Next 10 |
2024-03-14 13:30:17 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q4 2023 Earnings Call Mar 14, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q4 2023 Earnings Call Transcript
2024-03-14 11:57:11 ET Agenus Inc. (AGEN) Q4 2023 Results Conference Call March 14, 2024 08:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and Chief Executive Officer Steven O'Day - Chief Medical Officer Christine ...
2024-03-14 07:31:04 ET More on Agenus Agenus: A Would-Be Rockstar Held Back By Middling Financials Agenus: Taking Advantage Of The Risk-Reward Opportunity Agenus: 2024 May Finally Be The Year For A Major Turnaround Agenus Q4 2023 Earnings Preview Gink...
FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1 st and 2 nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metast...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
2024-03-13 12:31:02 ET More on Agenus Agenus: A Would-Be Rockstar Held Back By Middling Financials Agenus: Taking Advantage Of The Risk-Reward Opportunity Agenus: 2024 May Finally Be The Year For A Major Turnaround Ginkgo, Agenus win $31M contract to research...
2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...
Preclinical findings demonstrate superior pharmacological activity, offering a differentiated mechanism-of-action to enhance anti-tumor immunity in advanced solid cancers Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agen...
Conference Call on Thursday, March 14, 2024 at 8:30 a.m. ET Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Bioph...
News, Short Squeeze, Breakout and More Instantly...
2024-03-14 13:30:17 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q4 2023 Earnings Call Mar 14, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q4 2023 Earnings Call Transcript
FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1 st and 2 nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metast...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...